Vice President Vetter Development Service External Affairs
Jörg Zimmermann is currently Vice President External Affairs for Vetter Pharma Fertigung GmbH&Co KG, Ravensburg, Germany. In this role, he manages the relationships with regulatory agencies, professional organizations and other partners in the pharmaceutical industry. Before taking this role, he was responsible for Vetter Development Service which includes manufacturing science & process development, technology & process transfers, project & service analytics and drug delivery systems. Within Vetter, Jörg has held various positions in process implementation, new product introduction, lyophilization process development and as production manager before becoming Director of Production of Vetter's production site at Lake Constance in 2000. There he managed 5 production lines for aseptically prefilled injection systems. In September 2010 he became responsible for the process development and process introduction group at Vetter before being promoted to Vice President in November 2014. Jörg has volunteered as conference chair, track leader and speaker at conferences by ISPE, PDA, and Concept Heidelberg for over 20 years. Jörg served on the International Board of Directors of ISPE from 2016-2023 and was Chair of the Board in 2021/2022. Jörg studied pharmacy in Freiburg, Germany and Cardiff, Wales and is a registered pharmacist.
The unprecedented speed in the development and global rollout of vaccines and treatments for COVID-19 over the last two years has made it possible to get back to a new normal. The 2022 ISPE Facilities...
Pandemic or no pandemic, the pharmaceutical industry is growing at an unprecedented pace, and it is very gratifying to be part of that process. COVID-19 has brought our industry to the daily news, and while the public is getting a better grasp of how we work and need to work, there are still so many misconceptions that need clarification.
Who would have thought at the beginning of the pandemic that we would have several highly effective vaccines against the coronavirus and billions of doses administered by the end of 2021? I am still amazed what we as the pharmaceutical industry have achieved.
It is a great honour and pleasure for me as Chair of the ISPE Board of Directors and Chair of the 2022 ISPE Aseptic Conference Program Committee to give you an overview of the upcoming conference including information about the knowledge that will be shared, a look at some of the speakers, and details about a few of the networking opportunities.
The 30th ISPE Aseptic Conference culminated in the interactive regulatory panel, which offered attendees the unique opportunity to ask questions directly to the regulators.